Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

BACKGROUND: Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of panobinostat in combination with imatinib (IM) for treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, S, Hilger, R A, Mühlenberg, T, Grabellus, F, Nagarajah, J, Hoiczyk, M, Reichardt, A, Ahrens, M, Reichardt, P, Grunewald, S, Scheulen, M E, Pustowka, A, Bock, E, Schuler, M, Pink, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950855/
https://www.ncbi.nlm.nih.gov/pubmed/24434430
http://dx.doi.org/10.1038/bjc.2013.826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950855/
https://www.ncbi.nlm.nih.gov/pubmed/24434430
http://dx.doi.org/10.1038/bjc.2013.826

Ejemplares similares